GSK
GSK | NYSE
$49.78
-$0.94 (-1.85%)
At close: Sep 23, 2026, 3:43 PM ET
$49.71
-$0.07 (-0.14%)
After-hours:
Sep 23, 2026, 5:57 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | 437.26M | 1.84B | 627.73M | 2.71B | 1.65B | 1.77B | 501M | 65M | 1.3B | 1.33B | 434.21M | 1.53B | 1.75B | 1.63B | 1.76B | 892.29M | 350M | 1.77B | 574.14M | 1.21B | 1.7B | 1.26B |
Depreciation & Amortization | 224.16M | 463M | 782.68M | 995.06M | 1.16B | 823M | 412M | 951M | 639M | 696.1M | 1.46B | 579M | 452M | 640M | 8.21M | 1.57B | 631M | 418M | 413.76M | 1.25B | 762.22M | 361M |
Stock-Based Compensation | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Working Capital | -12.11M | -1.08B | 1.38B | -1.07B | -1.03B | -788M | 3.76B | -740M | -618M | -394.33M | 1.82B | 164M | -1.99B | -840M | 921.07M | -581.87M | 473M | -479M | 2.12B | -545.62M | -383.28M | -539M |
Other Non-Cash Items | 1.89B | -79M | -757.59M | 385.16M | 322M | -662M | -2.34B | 1.88B | -212M | -437.44M | 971.48M | -65M | 1.1B | -1.38B | 19.12M | -429.51M | 181M | 832M | 2.76B | 1.59B | -726.95M | -751M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.07B | n/a | n/a | n/a | -957.94M | n/a | n/a | n/a | -1.16B | n/a | n/a | n/a |
Change in Working Capital | -12.11M | -1.08B | 1.38B | -1.07B | -1.03B | -788M | 3.76B | -740M | -618M | -394.33M | 1.82B | 164M | -1.99B | -840M | 921.07M | -581.87M | 473M | -479M | 2.12B | -545.62M | -383.28M | -539M |
Operating Cash Flow | 2.54B | 1.14B | 2.04B | 3.03B | 2.1B | 1.15B | 2.33B | 2.15B | 1.11B | 1.19B | 3.62B | 2.21B | 1.31B | 53M | 1.75B | 1.45B | 1.64B | 2.54B | 4.7B | 3.5B | 1.35B | 331M |
Capital Expenditures | -328.95M | -443M | -560.25M | -428.37M | -633M | -448M | -1.14B | -842M | -442M | -314.45M | -587.28M | -497M | -535M | -529M | -509.57M | -328.15M | -426M | -570M | -504.16M | -310.47M | -212.99M | -354M |
Cash Acquisitions | -659.06M | -1.17B | -2.74B | -1.15B | -36M | -826M | -96M | -17M | 1.17B | -914.19M | 20.82M | -73M | -542M | -52M | 144.42M | -3.81B | -73M | -70M | -14.03M | -13.97M | 14.17M | -85M |
Purchase of Investments | -19.08M | n/a | -39.12M | -10.82M | n/a | n/a | n/a | n/a | n/a | -22.82M | -125.87M | -33M | -3M | -56M | -23.67M | -76.82M | -14M | n/a | -19.55M | -33.05M | -29.25M | 18M |
Sales Maturities Of Investments | 161.82M | n/a | 49.63M | 174.4M | n/a | n/a | n/a | n/a | n/a | 1.37B | 1.25B | 72M | 799M | 11M | 147.33M | 143.39M | 1M | n/a | 1.53M | 30.8M | 564.79M | 18M |
Other Investing Acitivies | 290.34M | -79M | 1.37B | 43.51M | -333M | -110M | -479M | -409M | -97M | 30.43M | 88.87M | 40M | -683M | 218M | 209.78M | -702.09M | -33M | -3.33B | 276.37M | 31.24M | -47.07M | 202M |
Investing Cash Flow | -880.86M | -1.47B | -2.36B | -2.15B | -625M | -1.14B | -1.12B | -731M | 770M | -254.86M | 292.18M | -491M | -964M | -408M | -385.03M | -5.01B | -545M | -3.59B | -472.18M | -1.65B | -273.59M | -48M |
Debt Repayment | -639.74M | 1.18B | 535.15M | -78.53M | -1.5B | 1.92B | 244M | -548M | -539M | -409.55M | -3.43B | -1.04B | 1.04B | 408M | 909.44M | -1.32B | -2.82B | -51M | -1.95B | -311.85M | -486.04M | -5M |
Common Stock Repurchased | -308.45M | -326M | n/a | -448.05M | -561M | -247M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -2M | n/a | 3.9M | 4M | -7M | n/a | n/a | n/a | n/a |
Dividend Paid | -728.54M | -643M | -628.49M | -905.47M | -656M | -612M | -612M | -612M | -652M | -720.19M | -674.37M | -567M | -557M | -555M | -696.95M | -799.51M | -1.16B | -952M | -1.26B | -1.32B | -1.62B | -946M |
Other Financial Acitivies | -228.03M | 51M | 900.86M | -275.12M | 342M | -213M | -474M | -81M | -394M | -147.08M | 43.51M | -151M | -451M | -177M | -1.52B | 364.48M | -521M | 8.98B | -127.86M | -243.22M | -301.38M | -440M |
Financial Cash Flow | -1.9B | 272M | 808.46M | -1.71B | -2.37B | 858M | -842M | -1.24B | -1.58B | -1.25B | -4.06B | -1.76B | 31M | -318M | -1.31B | -1.75B | -4.49B | 7.97B | -3.33B | -1.87B | -2.4B | -1.38B |
Net Cash Flow | -312.93M | -51M | 97.89M | -494.65M | -927M | 848M | 375M | 149M | 291M | -218.35M | -134.87M | -18M | 317M | -704M | 453.02M | -3.83B | -3.33B | 6.93B | 1.13B | -183.37M | -1.72B | -1.13B |
Free Cash Flow | 2.21B | 698M | 1.48B | 2.6B | 1.46B | 697M | 1.19B | 1.31B | 671M | 876.15M | 3.03B | 1.72B | 772M | -476M | 1.24B | 1.12B | 1.21B | 1.97B | 4.2B | 3.19B | 1.14B | -23M |
Adj. Free Cash Flow | 2.21B | 698M | 1.48B | 2.6B | 1.46B | 697M | 1.19B | 1.31B | 671M | 876.15M | 3.03B | 1.72B | 772M | -476M | 1.24B | 1.12B | 1.21B | 1.97B | 4.2B | 3.19B | 1.14B | -23M |
Maintenance CapEx | -224.16M | -443M | -349.4M | -203.22M | -590.07M | -383.61M | -1.11B | -842M | -138.66M | -137.43M | -292.51M | -358.34M | -426.43M | -529M | -509.57M | n/a | n/a | -570M | -154.19M | -310.47M | -212.99M | -354M |
Growth CapEx | -104.79M | n/a | -210.85M | -225.15M | -42.93M | -64.39M | -27.93M | n/a | -303.34M | -177.02M | -294.76M | -138.66M | -108.57M | n/a | n/a | -328.15M | -426M | n/a | -349.97M | n/a | n/a | n/a |
Owner Earnings | 2.31B | 698M | 1.69B | 2.82B | 1.51B | 761.39M | 1.22B | 1.31B | 974.34M | 1.05B | 3.33B | 1.85B | 880.57M | -476M | 1.24B | 1.45B | 1.64B | 1.97B | 4.55B | 3.19B | 1.14B | -23M |
Add to Watchlist
Select watchlists to add or remove GSK